Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3VM1001 Cream for Post-Herpetic Neuralgia
NCT03421613Phase 1Completed
- Sponsor
- CDA Research Group
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 3VM1001 in postherpetic neuralgia (PHN) (2 arms), sponsored by CDA Research Group. Primary endpoint: Visual Analog Scale at 25 days. Started Mar 2017; status: completed.
02
Drugs
3VM1001
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT03421613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421613.